Regenera set to begin Singapore trials
Tuesday, 03 August, 2004
Regenera (ASX: RGA) has received ethics committee approval to begin Phase III human clinical trials for its synthetic steroid drug Visagen at the Singapore Eye Research Institute.
The initial trial will test the treatment on cystoid macular oedema, and the company plans to expand the study with trials evaluating the therapy in age related macular degeneration, uveitis, diabetic macular oedema and as a co-treatment with photodynamic therapy.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
